Ranbaxy Laboratories has reported results for third quarter ended December 31, 2013.
The company has reported a net loss of Rs 1420.48 crore for the quarter as compared to net loss of Rs 395.96 crore for the same quarter in the previous year. Total income of the company has decreased 25.92% at Rs 1027.6 crore for Q3FY15 as compared Rs 1387.16 crore for the corresponding quarter previous year.
On the consolidated basis, the group has reported a net loss after taxes and Minority Interest of Rs 1029.72 crore for the quarter as compared to net loss of Rs 158.94 crore for the same quarter in the previous year. Total income of the company has decreased by 10.23% at Rs 2629.52 crore for quarter under review as compared to Rs 2929.23 crore for the quarter ended December 31, 2013.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1652.00 |
| Dr. Reddys Lab | 1235.20 |
| Cipla | 1211.30 |
| Zydus Lifesciences | 923.10 |
| Lupin | 2312.35 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: